^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TRS005
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Zhejiang Teruisi Biopharma
Drug class:
Microtubule inhibitor, CD20-targeted antibody-drug conjugate
Related drugs:
Phase 1
Zhejiang Teruisi Pharmaceutical Inc.
Recruiting
Last update posted :
10/25/2023
Initiation :
09/08/2020
Primary completion :
12/31/2023
Completion :
12/31/2024
CD20
|
CD20 positive
|
TRS005
Share
